Background: Mantle Cell Lymphoma MCL is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease, therapeutic resistance is of great interest.
However, knowledge about the biological mechanisms underlying resistance associated with MCL therapies and about associated predictors remains poor. We here describe the study background, design and methods used for this cohort.
Any such patient providing a signed informed consent is included. All subjects are followed up indefinitely, until refusal to participate in the study, emigration or death. Participants also complete standardized quality of life QOL questionnaires. In addition, participants are asked to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover predictive biomarkers and companion diagnostics.
If diagnostic biopsies are performed during the course of the disease, extracted biological samples are kept in a dedicated biobank. The integrative cohort at mid-term will be unique at producing a large variety of data that can be used to conceive the most effective personalized therapy for MCL patients.
Abstract Background: Mantle Cell Lymphoma MCL is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis.
